MedTrace Logo

Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors

NCT03398720 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-01-12

No results posted yet for this study

Summary

HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability of HTI-1066 in subjects with advanced solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

HTI-1066 dose level 1

Starting dose level

DRUG

HTI-1066 dose level 2

2nd dose level

DRUG

HTI-1066 dose level 3

3rd dose level

DRUG

HTI-1066 dose level 4

4th dose level

Sponsors & Collaborators

  • Jiangsu HengRui Medicine Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-12-31
Completion
2019-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03398720 on ClinicalTrials.gov